Invetx, a pioneer in protein-based therapeutics for animal health, announced that it has raised an additional US$10.25 million in its Series A financing, bringing the total round size to US$25.5 million. New investors include Casdin Capital and funds managed by Tekla Capital Management, joining existing lead investor Anterra Capital, as well as strategic investors AbCellera Biologics and WuXi Biologics.
Latham & Watkins LLP represented Invetx in the transaction with a corporate team led by Boston/New York partner Kristen Grannis, with Boston associates Spencer Ricks, Peter Prial and Tyler Mills.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
